Don’t Take “Negative” For An Answer with Kelly Radtke, PhD and Kelly Hagman, MS, CGC, LGC

• In this session, we will:

  • Define clinical validity and outline a published method for linking genes to diseases using a weighted scoring system guided by the ClinGen gene curation criteria.

  • Review how this approach is utilized to establish classification criteria of genes for clinical diagnostic exome testing, as well as for establishing multi-gene panel tests.

  • Demonstrate how lab-driven, continuous review of data to reclassify genes based on their clinical validity can impact patients who have previously received negative or inconclusive results.

  

  Only the live session qualifies for CEUs but when possible, we host the recordings on our website and NSGC recommends participants to use their personal email instead of work email addresses to ensure they receive their CEU certificates.

  

  Ambry Genetics is approved as a provider for continuing education program by NSGC and ASCLS P.A.C.E ® Program.

Kelly Radtke, PhD | Presenter

  

Kelly Radtke, PhD is the Manager of Rare Disease Scientists at Ambry Genetics and leads a team of PhD scientists in the analysis of diagnostic exome variants, maintaining an up-to-date clinical validity database, and reanalyzing and reclassifying previously reported exome cases. She participated in developing and publishing a framework for evaluation of clinical validity for clinical laboratory use. She participates in publication of novel genetic findings and methods and analyzes clinical diagnostic exome data to aid in genetic diagnosis of patients. She earned a Ph.D. for the University of California – Irvine for her work in Dr. Tom Schilling’s laboratory which analyzed genetic and developmental feedback mechanisms of the retinoic acid signaling pathway in patterning the early zebrafish embryo.

Kelly D. F. Hagman, MS, CGC | Presenter

  

Prior to receiving her masters in Genetic Counseling in 2004, Kelly Hagman spent several years in a research lab studying DNA mutagenesis. She started her career as a genetic counselor at the Molecular Diagnostic Laboratory at City of Hope, where she continued her involvement in research, most of which focused on Li-Fraumeni Syndrome (LFS). Driven by her interest in new molecular technologies, in 2009 Kelly joined Ambry Genetics to lead the genomic services group where she gained expertise in multiple sequencing platforms and DNA/RNA enrichment techniques. In 2011, she transitioned to the clinical team to lead Ambry's clinical genomics offerings, most notably, diagnostic exome sequencing. Kelly is currently the co-chair of the National Society of Genetic Counselors (NSGC) Genomic Technologies Special Interest Group (SIG). Kelly is also a firm believer that the best patient care is achieved through open data sharing. She has more than 35 peer-reviewed publications in molecular genetics (https://www.ncbi.nlm.nih.gov/myncbi/collections/mybibliography/) and has been an invited lecturer at several scientific meetings.